2 completed, 2 recruiting, 1 active not recruiting, 1 terminated. 7 Phase 2, 1 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 7 | Completed 2, Recruiting 2, Active not recruiting 1, Terminated 1, Withdrawn 1 |
| Phase 1 | 1 | Completed 1 |
Follow Recurrent High Grade B-Cell Lymphoma: new trials by email Literature Review of Recurrent High Grade B-Cell Lymphoma trials Research Report on Recurrent High Grade B-Cell Lymphoma
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Odronextamab for Relapsed and Refractory Large B-cell Lymphomas Before CAR-T Odronextamab, Biospecimen Collection, Bone Marrow Aspiration - Recurrent Diffuse Large B-Cell Lymphoma, Recurrent Diffuse Large B-Cell Lymphoma, Not Otherwise Specified | Phase 2 | Recruiting | University of Washington | 27 | 2025-09-04 | 2026-08-28 |
| Loncastuximab Tesirine and Mosunetuzumab for the Treatment of Relapsed or Refractory Diffuse Large B-Cell Lymphoma Biopsy, Biospecimen Collection, Computed Tomography - Recurrent Diffuse Large B-Cell Lymphoma, Recurrent Grade 3b Follicular Lymphoma | Phase 2 | Recruiting | City of Hope Medical Center | 36 | 2024-01-02 | 2026-10-08 |
| TTI-622 in Combination With Pembrolizumab for the Treatment of Relapsed or Refractory Diffuse Large B-Cell Lymphoma Biospecimen Collection, Computed Tomography, Ontorpacept - Recurrent ALK Positive Large B-Cell Lymphoma, Recurrent B-Cell Non-Hodgkin Lymphoma | Phase 2 | Active not recruiting | Mayo Clinic | 10 | 2023-04-19 | 2026-04-22 |
| Vorinostat and Combination Chemotherapy Before Donor Stem Cell Transplantation for the Treatment of Relapsed Aggressive B-cell or T-cell Non-Hodgkin Lymphoma Allogeneic Hematopoietic Stem Cell Transplantation, Busulfan, Clofarabine - Recurrent Aggressive Non-Hodgkin Lymphoma, Recurrent B-Cell Non-Hodgkin Lymphoma | Phase 2 | Withdrawn | M.D. Anderson Cancer Center | 2021-10-29 | 2024-01-12 | |
| Anakinra for the Reduction of CAR-T Toxicity in Patients With Relapsed or Refractory Large B-cell Lymphoma Anakinra, Axicabtagene Ciloleucel, Cyclophosphamide - Hematopoietic and Lymphoid Cell Neoplasm, Recurrent Diffuse Large B-Cell Lymphoma | Phase 2 | Completed | M.D. Anderson Cancer Center | 22 | 2020-07-27 | 2025-01-28 |
| Anakinra in Preventing Severe Chimeric Antigen Receptor T-Cell Related Encephalopathy Syndrome in Patients With Recurrent or Refractory Large B-cell Lymphoma Anakinra, Axicabtagene Ciloleucel, Cyclophosphamide - Diffuse Large B-Cell Lymphoma, Not Otherwise Specified, High Grade B-Cell Lymphoma | Phase 2 | Terminated | Jonsson Comprehensive Cancer Center | 23 | 2020-03-04 | 2026-02-27 |
| Mogamulizumab and Pembrolizumab in Treating Patients With Relapsed or Refractory Diffuse Large B Cell Lymphoma Mogamulizumab, Pembrolizumab - Recurrent Diffuse Large B-Cell Lymphoma, Recurrent High Grade B-Cell Lymphoma | Phase 1 / Phase 2 | Completed | National Cancer Institute (NCI) | 8 | 2018-10-24 | 2023-09-21 |
Lymphoma, Large B-Cell, Diffuse (7) · Lymphoma, B-Cell (2) · Burkitt Lymphoma (1) · Disease Progression (1) · Hematologic Neoplasms (1) · Lymphoma, T-Cell (1)
Hemic and Lymphatic Diseases (7) · Immune System Diseases (7) · Immunoproliferative Disorders (7) · Lymphatic Diseases (7) · Lymphoma (7) · Lymphoma, Non-Hodgkin (7) · Lymphoproliferative Disorders (7) · Neoplasms (7) · Neoplasms by Histologic Type (7) · Lymphoma, B-Cell (5) · DNA Virus Infections (1) · Disease Attributes (1) · Epstein-Barr Virus Infections (1) · Hematologic Diseases (1) · Herpesviridae Infections (1)
Biopsy (3) · Cyclophosphamide (3) · Magnetic Resonance Spectroscopy (3) · Specimen Handling (3) · Interleukin 1 Receptor Antagonist Protein (2) · Receptors, Interleukin-6 (2) · axicabtagene ciloleucel (2) · fludarabine (2) · pembrolizumab (2) · Busulfan (1) · CT-P10 (1) · Clofarabine (1) · Disulfides (1) · Gemcitabine (1) · Immunoglobulin G (1)
M.D. Anderson Cancer Center (2) · City of Hope Medical Center (1) · Jonsson Comprehensive Cancer Center (1) · Mayo Clinic (1) · National Cancer Institute (NCI) (1) · University of Washington (1)
United States (6)
Erel Joffe (1) · John M Timmerman, MD (1) · Mengyang Di, MD, PhD (1) · Paolo Strati (1) · Stephen M. Ansell, MD, PhD (1) · Swetha Kambhampati (1) · Yago L Nieto (1)
P30CA033572 (1), UM1CA186691 (1)